AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30174951 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg and pregabalin 75mg twice daily starting from 3 days before the operation
Number of subjects: 30
Study 30174951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30174951 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 30
Study 30174959 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK Interspinous Spacer (IS)
Number of subjects: 55
Study 30174959 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon Interspinous Spacer (IS)
Number of subjects: 55
Study 30174959 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IS)
Number of subjects: 55
Study 30175123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (Ozurdex, Allergan)
Number of subjects: 26
Study 30175246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 30175246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30175268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 30176179 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 685
Study 30176673 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone plus patiromer
Number of subjects: 146
Study 30176673 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone plus placebo
Number of subjects: 146
Study 30176833 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 75
Study 30176833 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and hormonal therapy
Number of subjects: 75
Study 30176833 — intervention group
Group type: COMPARATOR
Intervention: Healthy post-menopausal women
Number of subjects: 75
Study 30176875 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow concentrate (BMC) and platelet products injection
Number of subjects: 29
Study 30176878 — intervention group
Group type: EXPERIMENTAL
Intervention: Iconic Therapy
Number of subjects: 72
Study 30176878 — intervention group
Group type: COMPARATOR
Intervention: Structured Support Therapy
Number of subjects: 72
Study 30176893 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 10
Study 30176943 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive early passive and active movement program
Number of subjects: 100
Study 30176943 — intervention group
Group type: COMPARATOR
Intervention: Limited early passive movement program (usual care)
Number of subjects: 100
Study 30176976 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) therapy adherence (h/night)
Number of subjects: 252
Study 30177021 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (an oral prodrug SYK inhibitor)
Number of subjects: 0
Study 30177021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30177258 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric healthcare workers
Number of subjects: 65
Study 30177258 — intervention group
Group type: COMPARATOR
Intervention: Non-healthcare workers
Number of subjects: 65
Study 30177258 — intervention group
Group type: COMPARATOR
Intervention: Infants
Number of subjects: 65
Study 30177258 — intervention group
Group type: COMPARATOR
Intervention: Children
Number of subjects: 65
Study 30177258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 65
Study 30177258 — intervention group
Group type: COMPARATOR
Intervention: T-cells
Number of subjects: 65
Study 30177273 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with subclinical cardiac disease
Number of subjects: 581
Study 30177273 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with subclinical cardiac disease
Number of subjects: 581
Study 30177353 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with colic (37 infants)
Number of subjects: 65
Study 30177353 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk, formula, or breast + formula feeding in infants with colic
Number of subjects: 65
Study 30177353 — intervention group
Group type: COMPARATOR
Intervention: Noncolicky infants (28 infants)
Number of subjects: 65
Study 30177423 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentry bioconvertible inferior vena cava (IVC) filter
Number of subjects: 129
Study 30178032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (125 mg/m2) plus gemcitabine (1000 mg/m2) administered on days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxic effects.
Number of subjects: 74
Study 30178032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus gemcitabine regimen.
Number of subjects: 74
Study 30178312 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg16Gly heterozygous group
Number of subjects: 58
Study 30178312 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous G mutant
Number of subjects: 58
Study 30178312 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln27Glu C wild group
Number of subjects: 58
Study 30178312 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln27Glu G mutant group
Number of subjects: 58
Study 30178312 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous Arg16Gly and Gln27Glu
Number of subjects: 58
Study 30178312 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous wild and mutant
Number of subjects: 58
Study 30178481 — intervention group
Group type: EXPERIMENTAL
Intervention: CTL019 infusion
Number of subjects: 51
Study 30178528 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental drug
Number of subjects: 0
Study 30178528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30178605 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D transperineal ultrasound
Number of subjects: 57
Study 30178605 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 57
Study 30178605 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement assessment
Number of subjects: 57
Study 30179569 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv) 1.8 mg/kg once every 3 weeks followed by six cycles of AVD chemotherapy and four consolidative doses of Bv
Number of subjects: 48
Study 30179569 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv)
Number of subjects: 48
Study 30179569 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv) and AVD chemotherapy
Number of subjects: 48
Study 30180050 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension (USLS) with a size 'small' titanium vascular clip applied to the base of each suture.
Number of subjects: 15
Study 30180407 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 0
Study 30180831 — intervention group
Group type: EXPERIMENTAL
Intervention: RP intervention
Number of subjects: 290
Study 30180831 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 290
Study 30180845 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive communication reported by women
Number of subjects: 867
Study 30180845 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive use reported by women
Number of subjects: 867
Study 30180845 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive communication reported by husbands
Number of subjects: 867
Study 30180845 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive use reported by husbands
Number of subjects: 867
Study 30180867 — intervention group
Group type: EXPERIMENTAL
Intervention: Single SBRT fraction of 19 Gy to the whole prostate gland with urethra-sparing (17 Gy)
Number of subjects: 0
Study 30180873 — intervention group
Group type: EXPERIMENTAL
Intervention: (1,3)-β-D-glucan (BDG) group
Number of subjects: 312
Study 30180873 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 312
Study 30180887 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) consisting of four 5-min cycles of limb ischemia and reperfusion after induction of anesthesia
Number of subjects: 0
Study 30180887 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 30180909 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS neurofeedback intervention
Number of subjects: 10
Study 30180944 — intervention group
Group type: EXPERIMENTAL
Intervention: NKG2D CAR T cells infused fresh after a 9-day process
Number of subjects: 0
Study 30181045 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose (DD) influenza vaccine (30 µg antigen)
Number of subjects: 79
Study 30181045 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) influenza vaccine (15 µg antigen)
Number of subjects: 79
Study 30181173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab (LR)
Number of subjects: 38
Study 30181172 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab (or tocilizumab if siltuximab is not available) with or without corticosteroids
Number of subjects: 344
Study 30181172 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy
Number of subjects: 344
Study 30181172 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional agents tailored by disease severity
Number of subjects: 344
Study 30181172 — intervention group
Group type: EXPERIMENTAL
Intervention: Response criteria
Number of subjects: 344
Study 30181185 — intervention group
Group type: EXPERIMENTAL
Intervention: Violet LED treatment (405 nm)
Number of subjects: 80
Study 30181185 — intervention group
Group type: EXPERIMENTAL
Intervention: Violet LED + 35% carbamide peroxide
Number of subjects: 80
Study 30181185 — intervention group
Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (gold standard)
Number of subjects: 80
Study 30181315 — intervention group
Group type: EXPERIMENTAL
Intervention: IBM Watson for Oncology (WFO) recommendations
Number of subjects: 362
Study 30181415 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapeutics against the RAS/RAF/MEK/ERK pathway
Number of subjects: 0
Study 30181780 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon β-1a every 2 weeks
Number of subjects: 0
Study 30181780 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon β-1a every 4 weeks
Number of subjects: 0
Study 30181780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30181780 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall NEDA
Number of subjects: 0
Study 30181874 — intervention group
Group type: EXPERIMENTAL
Intervention: WISE intervention (nutrition education)
Number of subjects: 49
Study 30181874 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct assessment of fidelity
Number of subjects: 49
Study 30181874 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect assessment of fidelity
Number of subjects: 49
Study 30182209 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy for mCRC
Number of subjects: 756
Study 30182209 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment among diabetic patients
Number of subjects: 756
Study 30183115 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher driving pressure (ΔP) measured at ICU admission or 24 hours later
Number of subjects: 221
Study 30184299 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg twice daily by vaginal suppository) during add-back phase
Number of subjects: 37
Study 30184299 — intervention group
Group type: COMPARATOR
Intervention: Gonadal suppression induced by leuprolide acetate (3.75 mg IM monthly)
Number of subjects: 37
Study 30184299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PMDD)
Number of subjects: 37
Study 30184559 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR clinical decision support (CDS) tool for TBI prediction
Number of subjects: 38
Study 30185117 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive intraperitoneal lavage (EIPL)
Number of subjects: 27
Study 30185117 — intervention group
Group type: COMPARATOR
Intervention: Control (no EIPL)
Number of subjects: 27
Study 30185165 — intervention group
Group type: EXPERIMENTAL
Intervention: CareToy revised (CT-R) intervention
Number of subjects: 42
Study 30185165 — intervention group
Group type: COMPARATOR
Intervention: Infant Massage (IM) intervention
Number of subjects: 42
Study 30185213 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline ventricular size with low cognitive reserve panel (CR-P) in men
Number of subjects: 723
Study 30185213 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline ventricular size with low cognitive reserve panel (CR-P) in women
Number of subjects: 723
Study 30185228 — intervention group
Group type: EXPERIMENTAL
Intervention: pictilisib (GDC-0941) plus paclitaxel (90 mg/m²)
Number of subjects: 69
Study 30185407 — intervention group
Group type: COMPARATOR
Intervention: Center-near multifocal design contact lens in the more hyperopic eye
Number of subjects: 0
Study 30185407 — intervention group
Group type: COMPARATOR
Intervention: Single-vision contact lens in the fellow eye if required
Number of subjects: 0
Study 30185407 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-near multifocal design contact lenses in each eye
Number of subjects: 0
Study 30185407 — intervention group
Group type: COMPARATOR
Intervention: Natural progression without any intervention
Number of subjects: 0
Study 30185431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) 2 times per day continuously in 28-day cycles for the first 3 cycles
Number of subjects: 0
Study 30185431 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) 25 mg/m2
Number of subjects: 0
Study 30186045 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 500
Study 30186323 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 30186323 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 0
Study 30186623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (Kanarb), switched to after 8 weeks of treatment
Number of subjects: 12244
Study 30187270 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFNT)
Number of subjects: 15
Study 30187270 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 15
Study 30187421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentorship programs in bariatric surgery
Number of subjects: 293
Study 30187599 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a 180 μg/wk added to ongoing nucleos(t)ide analogue therapy
Number of subjects: 70
Study 30188978 — intervention group
Group type: EXPERIMENTAL
Intervention: Allometric miltefosine dosing for 28 days
Number of subjects: 30
Study 30188978 — intervention group
Group type: COMPARATOR
Intervention: Linear miltefosine dosing (2.5 mg/kg/day for 28 days)
Number of subjects: 30
Study 30189049 — intervention group
Group type: EXPERIMENTAL
Intervention: Onclarity HPV testing
Number of subjects: 1960
Study 30189049 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Capture 2 (HC2)
Number of subjects: 1960
Study 30189049 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV genotyping
Number of subjects: 1960
Study 30189345 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 80
Study 30189345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30189858 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal MRI techniques
Number of subjects: 0
Study 30189858 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment and multi-modal MR imaging examination
Number of subjects: 0
Study 30189858 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging features acquisition
Number of subjects: 0
Study 30189858 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical information collection
Number of subjects: 0
Study 30189902 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 662
Study 30189902 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide
Number of subjects: 662
Study 30189911 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 6-7 hours/week
Number of subjects: 130
Study 30189911 — intervention group
Group type: EXPERIMENTAL
Intervention: Sometimes seeking shade
Number of subjects: 130
Study 30189911 — intervention group
Group type: EXPERIMENTAL
Intervention: Rarely/never seeking shade
Number of subjects: 130
Study 30189911 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a hat rarely/never (in school children)
Number of subjects: 130
Study 30190005 — intervention group
Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 54
Study 30190030 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-focused assessment (National Institute for Health and Care Excellence guidelines)
Number of subjects: 13773
Study 30190030 — intervention group
Group type: COMPARATOR
Intervention: Risk-based assessment (American College of Cardiology/American Heart Association and European Society of Cardiology guidelines)
Number of subjects: 13773
Study 30190030 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-high-risk groups (compared to low-risk groups)
Number of subjects: 13773
Study 30190030 — intervention group
Group type: COMPARATOR
Intervention: All guidelines
Number of subjects: 13773
Study 30190041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 267
Study 30190041 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness assessed using the Epworth Sleepiness Scale (ESS)
Number of subjects: 267
Study 30190271 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal samples from the AR group
Number of subjects: 39
Study 30190271 — intervention group
Group type: EXPERIMENTAL
Intervention: Th2 scores in the nose and bronchi
Number of subjects: 39
Study 30190271 — intervention group
Group type: EXPERIMENTAL
Intervention: Th17 scores
Number of subjects: 39
Study 30190271 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cells
Number of subjects: 39
Study 30190299 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle
Number of subjects: 2872
Study 30190299 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib-related treatment-emergent adverse events (TEAEs)
Number of subjects: 2872
Study 30190299 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory toxicities
Number of subjects: 2872
Study 30190302 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC105 (8 mg/kg and then 10 mg/kg weekly) in combination with axitinib (initially at 5 mg b.i.d. and escalated to a maximum of 10 mg b.i.d.)
Number of subjects: 18
Study 30190302 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC105 (8 mg/kg and then 10 mg/kg weekly) in combination with axitinib
Number of subjects: 18
Study 30190681 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30191053 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic intra-arterial chemotherapy (IACHT) with Epirubicin-Cisplatin and systemic chemotherapy (SCHT) with Capecitabine or 5-fluorouracil, followed by gemcitabine-based maintenance therapy.
Number of subjects: 145
Study 30191097 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert/advice (n=198)
Number of subjects: 582
Study 30191097 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice-only (n=185)
Number of subjects: 582
Study 30191097 — intervention group
Group type: COMPARATOR
Intervention: Control (n=199)
Number of subjects: 582
Study 30191097 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample (N=543)
Number of subjects: 582
Study 30191097 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up (n=377) after 52 weeks
Number of subjects: 582
Study 30191144 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated and person-centered interventions
Number of subjects: 0
Study 30191144 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive studies
Number of subjects: 0
Study 30191144 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-to-Action Framework and Complexity Model
Number of subjects: 0
Study 30191465 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 600
Study 30191464 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 µg + ICS/LABA
Number of subjects: 1637
Study 30191464 — intervention group
Group type: COMPARATOR
Intervention: Placebo + ICS/LABA
Number of subjects: 1637
Study 30191502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 280
Study 30191502 — intervention group
Group type: COMPARATOR
Intervention: Behavioral/pharmacological treatment
Number of subjects: 280
Study 30191523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg orally three times daily plus hydrocortisone (20 mg in the morning and 10 mg at night) and lenalidomide 25 mg orally daily for 21 days in a 28-day cycle and aspirin 75 mg daily
Number of subjects: 34
Study 30191864 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a dose of 40 Gy in 5 fractions of 8 Gy
Number of subjects: 309
Study 30191864 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 309
Study 30192444 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (maximum dose of 21.0 mg/d, applied daily with dose escalation)
Number of subjects: 15
Study 30192949 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-13 levels
Number of subjects: 277
Study 30192949 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ/IL-13 ratio and IL-10 levels
Number of subjects: 277
Study 30193554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (CET)
Number of subjects: 30
Study 30193554 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 30194205 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy
Number of subjects: 199
Study 30194205 — intervention group
Group type: COMPARATOR
Intervention: 21 Gy
Number of subjects: 199
Study 30194585 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 40 mg oral dose of imarikiren
Number of subjects: 0
Study 30194585 — intervention group
Group type: COMPARATOR
Intervention: Normal renal or hepatic function (control group)
Number of subjects: 0